Author

Ahmed Rattani

Beth Israel Deaconess Medical CenterORCID 0000-0002-1058-7314Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Aedín C. CulhaneiD· 1 shared Andrew D. KellyiD· 1 shared Benjamin Haibe‐KainsiD· 1 shared Cassandra C. Garbutt· 1 shared Christopher E. LietziD· 1 shared Cora E. AndersoniD· 1 shared Dimitrios SpentzosiD· 1 shared Edwin ChoyiD· 1 shared

Activity by Year

2019-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenetic & Genomic Medicine

Aedín C. CulhaneORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistrybioRxivPreprintOct 12, 2025

The Wnt/APC destruction complex targets SREBP2 in a β-catenin-independent pathway to control cholesterol metabolism

Ahmed Rattani, Cora E. Anderson, William V. Trim…·Marc W. Kirschner

This study identifies SREBP2 as a direct APC-AXIN1 substrate degraded via a β-catenin-independent pathway, regulating cholesterol metabolism and providing a target for APC-mutant colorectal cancer.

1 citation

Xenopusmouse

𝕏 PostBluesky

Genetic & Genomic MedicinemedRxivPreprintSep 27, 2019

Machine learning-based prediction of response to PARP inhibition across cancer types.

Katherine E. Hill, Ahmed Rattani, Christopher E. Lietz…·Dimitrios Spentzos

The paper develops a multi-gene signature predicting PARP inhibitor response across cancer types using machine learning and validates it in vitro and in clinical datasets.

2 citations

humanbulk RNA-seq

𝕏 PostBluesky